corifollitropin alfa + human chorionic gonadotropin

**Corifollitropin alfa + human chorionic gonadotropin** is a combination regimen used primarily in reproductive medicine. Corifollitropin alfa is a long-acting recombinant analog of follicle-stimulating hormone (FSH), engineered for sustained follicular stimulation and extended activity, enabling the development of multiple ovarian follicles with fewer injections compared to traditional FSH therapies[1][2][3][5]. In women, this combination is used to stimulate controlled ovarian hyperstimulation, typically as part of assisted reproductive technology (ART) protocols, in combination with a GnRH antagonist and with hCG for ovulation induction[1][2][3][4]. In adolescent and adult males with hypogonadotropic hypogonadism, corifollitropin alfa in combination with hCG stimulates spermatogenesis and testicular growth; hCG triggers luteinizing hormone (LH) release, leading to increased testosterone secretion and sperm production[1][4][5]. - **Mechanism of corifollitropin alfa:** Recombinant analog of FSH, stimulating granulosa cells in the ovary or Sertoli cells in the testis for follicular or spermatogenic development. - **Mechanism of hCG:** hCG is an LH analog, acting on the LH/choriogonadotropin receptor to induce ovulation in women or to stimulate Leydig cells for testosterone production in men.

Brand names

ElonvaPregnyl

Other names

corifollitropin alfa + hCG